bexobrutideg Updated Jul 9
The Roche deal ($700M upfront, up to $2.3B total) already provided the major derisking catalyst, the stock surged ~70% on the June 8 announcement. Watch for HSR antitrust clearance (expected Q3 2026), Phase 3 trial initiation in CLL this summer, and any early data from planned Phase 2 starts in autoimmune (CSU) and neurology (MS). Analyst consensus is Strong Buy with mean PT of $31.44, but the stock already reflects significant partnership premium, new upside will require compelling Phase 2/3 data execution, not just partnership validation.
- Transformative Roche partnership provides $700M upfront, up to $2.3B total, validating the platform, eliminating near-term dilution risk, and providing a 50/50 U.S. profit share (Nurix press release / Reuters / Roche media release).
- Impressive Phase 1 data: 83% ORR and 22.1-month median PFS in heavily pretreated CLL patients who failed both BTK inhibitors and BCL-2 inhibitors (ASH 2025 / EHA 2026 presentations).
- CNS-penetrant property opens larger market opportunities in neurology (multiple sclerosis) and immunology (chronic spontaneous urticaria) beyond oncology, estimated total addressable market of ~$48B by 2030 (Nurix 8-K filing analysis).
- Roche partnership already priced in, stock surged ~70% premarket on the June 8 announcement; much of the upside may already be reflected at ~$24.69.
- Phase 3 trial vs Lilly's already-approved Jaypirca (pirtobrutinib) is a high-risk binary, Jaypirca has already demonstrated superiority over ibrutinib in Phase 3 and has a multi-year commercial head start.
- BTK degrader competition is intensifying: BeiGene's BGB-16673 and AbbVie's candidate are also in clinical development; this is a crowded, well-funded target space.